Skip to main
ELUT
ELUT logo

Elutia Inc (ELUT) Stock Forecast & Price Target

Elutia Inc (ELUT) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Elutia Inc. has demonstrated strong revenue growth in its BioEnvelope product line, with an 18% year-over-year increase to $2.7 million, attributed to the promising initial sales of its EluPro product. The company's gross margin improved significantly by 630 basis points year-over-year, reaching 42.5%, driven by a favorable product mix, while R&D expenses notably decreased by 40%, allowing for more strategic allocation towards growth initiatives. As EluPro transitions to full commercial launch and partners like Boston Scientific begin to sell the product, the company is well-positioned for upward earnings revisions and continued pipeline expansion, indicating strong future growth potential.

Bears say

Elutia Inc., which specializes in regenerative medicine, reported 3Q24 revenue of $5.9 million, falling short of both Cantor and FactSet consensus estimates, reflecting a year-over-year decline of approximately 3%. Notably, revenue from the company's BioEnvelope products decreased by 12%, driven by customers delaying orders for the EluPro product, while revenue from the Cardiovascular segment plummeted 40% to $0.6 million. Furthermore, a slower-than-anticipated sales trajectory, combined with potential regulatory setbacks and the reliance on a limited number of key products, poses significant risks to Elutia’s profitability and overall financial outlook.

Elutia Inc (ELUT) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elutia Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elutia Inc (ELUT) Forecast

Analysts have given Elutia Inc (ELUT) a Buy based on their latest research and market trends.

According to 2 analysts, Elutia Inc (ELUT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elutia Inc (ELUT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.